The company trades at a $17.5 million market cap (based on outstanding shares as of 2/12/13) • Over a 15-year period, the company has obtained and deployed over $53 million • The investment represented by the strategic financing announced today is 67.9% of this $53 million value • The transaction is expected to close by the end of this month (compare this to the 15 years it took VistaGen to obtain $53 million)
It doesn't take much math to project the rate at which VistaGen $VSTA will accelerate and expand its stem cell technology-based drug rescue, predictive toxicology, and drug metabolism programs
News 
Market Data 
Discover 
